Sinoway Industrial Co., Ltd.

Lacosamide 175481-36-4 Lacosamide 175481-36-4

Lacosamide 175481-36-4
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Lacosamide :

Name

Lacosamide

Alias

(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide

CAS NO.

175481-36-4

Molecular Formula

C13H18N2O3

Molecular Weight

250.29

EINECS

1308068-626-2

Brief Introduction

At present, there are more than 200,000 epilepsy patients in the world who have used lacosamide. Lacosamide is currently not approved in Japan or China for epilepsy treatment. 2012 UCB announced the launch of a Phase III clinical trial of lacosamide in Japan and China to study the efficacy and safety of lacosamide as an adjuvant therapy for adult patients with partial seizures. UCB obtained the rights to research on lacosamide in Japan at the end of 2010, and has since obtained worldwide rights to develop and sell lacosamide.

Storage condition

Room temperature, seal.


Use of Lacosamide:

Used in patients with ≥ 16-year-old epilepsy with or without secondary general attacks of partial seizure therapy. Antiepileptic effects are thought to regulate the slow inactivation of sodium channels, and their efficacy and tolerability have been shown in some randomized controlled trials. A single-center, large-scale cohort study found that the continuous use of lacosamide tablets for refractory epilepsy has a retention rate of 62% in one year, 45% in two years, and 35% in three years. 18% of patients reported significant reduction in seizures or episodes of cessation for more than 6 months during medication, with 4 episodes that stopped more than 1 year. Long-term efficacy is similar to zonisamide and pregabalin. The number of reported adverse events was 61%. The vast majority were associated with the central nervous system. Most are related to the central nervous system. Most clinical factors do not affect the retention rate, withdrawal is not due to adverse events, but often because of invalidity.

COA of Lacosamide :

Item

Standard

Result

Appearance

White powder

Conforms

Specific rotation

+15oC  to +17oC

+16.3 oC

Melting Point(/oC)

142-146oC

146 oC

Water(KP)

Not more than 0.5%

0.41%

Assay(HPLC)

Not less than 98.0%

98.27%

Conclusion

The product confirms to the standard


  • Prednisolone 50-24-8
    Basic information:Product Name: PrednisoloneMolecular Formula : C21H28O5Molecular Weight: 360.44CAS No.: 50-24-8Appearance: White crystalline powderSpecifications:EP8/USP38/BP2014Usages :It used for autoi... Prednisolone  50-24-8
  • Iron Sucrose 8047-67-4
    Basic informationOther Names: Iron(III) saccharateCAS No.: 8047-67-4 Appearance:Brown-dark liquid Document: GMP/DMF/Technical support.Appearance:Brown-dark liquid UsageAnti-anemia medicine, which ca... Iron Sucrose 8047-67-4
  • Entecavir 142217-69-4
    Basic information of EntecavirNameEntecavirAlias ETVCAS NO.142217-69-4Molecular FormulaC12H15N5O3Molecular Weight277.283Quality Standard96% minGrade StandardFood grade, Medicine gradePackage Size25kg/... Entecavir 142217-69-4
  • Hydrocortisone Acetate 50-03-3
    Basic informationProduct Name: Hydrocortisone AcetateMolecular Formula : C23H32O6Molecular Weight: 404.5CAS No.: 50-03-3Appearance: White crystalline powderSpecifications:EP8; EP6/USP37UsagesEczema, itchy... Hydrocortisone Acetate 50-03-3

MORE_DETAIL Lacosamide 175481-36-4

Basic information of Lacosamide :

Name

Lacosamide

Alias

(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide

CAS NO.

175481-36-4

Molecular Formula

C13H18N2O3

Molecular Weight

250.29

EINECS

1308068-626-2

Brief Introduction

At present, there are more than 200,000 epilepsy patients in the world who have used lacosamide. Lacosamide is currently not approved in Japan or China for epilepsy treatment. 2012 UCB announced the launch of a Phase III clinical trial of lacosamide in Japan and China to study the efficacy and safety of lacosamide as an adjuvant therapy for adult patients with partial seizures. UCB obtained the rights to research on lacosamide in Japan at the end of 2010, and has since obtained worldwide rights to develop and sell lacosamide.

Storage condition

Room temperature, seal.


Use of Lacosamide:

Used in patients with ≥ 16-year-old epilepsy with or without secondary general attacks of partial seizure therapy. Antiepileptic effects are thought to regulate the slow inactivation of sodium channels, and their efficacy and tolerability have been shown in some randomized controlled trials. A single-center, large-scale cohort study found that the continuous use of lacosamide tablets for refractory epilepsy has a retention rate of 62% in one year, 45% in two years, and 35% in three years. 18% of patients reported significant reduction in seizures or episodes of cessation for more than 6 months during medication, with 4 episodes that stopped more than 1 year. Long-term efficacy is similar to zonisamide and pregabalin. The number of reported adverse events was 61%. The vast majority were associated with the central nervous system. Most are related to the central nervous system. Most clinical factors do not affect the retention rate, withdrawal is not due to adverse events, but often because of invalidity.

COA of Lacosamide :

Item

Standard

Result

Appearance

White powder

Conforms

Specific rotation

+15oC  to +17oC

+16.3 oC

Melting Point(/oC)

142-146oC

146 oC

Water(KP)

Not more than 0.5%

0.41%

Assay(HPLC)

Not less than 98.0%

98.27%

Conclusion

The product confirms to the standard

Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//